PMID- 25720713
OWN - NLM
STAT- MEDLINE
DCOM- 20150909
LR  - 20181202
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 19
IP  - 3
DP  - 2015
TI  - Combination of thrombolytic therapy and neuroprotective therapy in acute ischemic 
      stroke: is it important?
PG  - 416-22
LID - 8443 [pii]
AB  - Tissue plasminogen activator (tPA) is the only treatment approved by the USA FDA 
      for acute ischemic stroke. There are many obstacles, however, when it is widely 
      used in clinical setting, such as narrow therapeutic window, cytotoxicity and 
      neurotoxicity. In recent years, many neuroprotective agents aiming to different 
      molecular targets in ischemic cascade have been rapidly developed. Although these 
      agents showed remarkable effects in experimental stroke, they failed to be 
      translated to clinical use for many reasons. As the concept of "neurovascular 
      unit" (NVU) is mentioned, combination of thrombolytic agents such as tPA with 
      neuroprotectants gets more and more attention. Evidences supporting the 
      combination therapy have been obtained from a variety of studies in many kinds of 
      animal models, even though clinical evidences are inadequate. Combination of 
      thrombolysis and neuroprotection has been considered as a promising approach for 
      treatment of acute ischemic stroke. There are many advantages for the combination 
      therapy. In this context, we review the sound rationales and researching 
      achievements to support the therapy.
FAU - Wang, Y
AU  - Wang Y
AD  - Department of Pharmacology, School of Life Science and Biopharmaceutical 
      Sciences, Shenyang Pharmaceutical University, Shenyang, China. 501907879@qq.com.
FAU - Li, Q
AU  - Li Q
FAU - Wang, J
AU  - Wang J
FAU - Zhuang, Q-K
AU  - Zhuang QK
FAU - Zhang, Y-Y
AU  - Zhang YY
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Neuroprotective Agents)
RN  - EC 3.4.21.68 (Tissue Plasminogen Activator)
SB  - IM
MH  - Animals
MH  - Drug Therapy, Combination
MH  - Fibrinolytic Agents/administration & dosage
MH  - Humans
MH  - Neuroprotective Agents/*administration & dosage
MH  - Stroke/diagnosis/*drug therapy
MH  - Thrombolytic Therapy/*methods
MH  - Tissue Plasminogen Activator/*administration & dosage
EDAT- 2015/02/28 06:00
MHDA- 2015/09/10 06:00
CRDT- 2015/02/28 06:00
PHST- 2015/02/28 06:00 [entrez]
PHST- 2015/02/28 06:00 [pubmed]
PHST- 2015/09/10 06:00 [medline]
AID - 8443 [pii]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2015;19(3):416-22.